Jia Libin, Lin Hongsheng, Oppenheim Joost, Howard O M Zack, Li Jie, Fan Huiting, Zhao Zhizheng, Farrar William, Zhang Ying, Colburn Nancy, Young Matthew R, Li Weidong, Newman David, O'Keefe Barry R, Beutler John, Liu Jikai, Hao Xiaojiang, Yang Xiaosheng, Ji Tengfei, White Jeffrey D
Office of Cancer Complementary and Alternative Medicine, Division of Cancer Treatment and Diagnosis, and Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD; Cancer Institute, China Academy of Chinese Medical Sciences, Beijing, China; Laboratory of Molecular Immunoregulation, Laboratory of Cancer Prevention, Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD; Natural Products Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD; Kunming Institute of Botany, China Academy of Sciences, Kunming, China; Key Laboratory of Chemistry for Natural Products in Guizhou Province, China Academy of Sciences, Gui Yang, China; Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China.
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx007.
Since 2007, the US National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine (OCCAM), together with the Cancer Institute of the China Academy of Chinese Medical Sciences (CICACMS), institutes at China Academy of Sciences and Chinese Academy of Medical Sciences, have engaged in collaborations on Chinese medicine (CM) and cancer research. Through these collaborations, CM drugs and compounds have been studied at NCI labs. This paper summarizes the discoveries and progress on these research projects, exploring the aspects of cancer prevention, botanical drug mechanisms of action and component analysis/quality control (QC), and anticancer activity screening. These and other related projects have been presented in various jointly convened workshops and have provided the backdrop for establishing a new organization, the International Consortium for CM and Cancer, to promote international collaborations in this field.
自2007年以来，美国国立癌症研究所（NCI）的癌症补充与替代医学办公室（OCCAM）与中国中医科学院癌症研究所（CICACMS）、中国科学院和中国医学科学院的各机构开展了中医药与癌症研究方面的合作。通过这些合作，NCI实验室对中药药物和化合物进行了研究。本文总结了这些研究项目的发现和进展，探讨了癌症预防、植物药作用机制及成分分析/质量控制（QC）以及抗癌活性筛选等方面。这些及其他相关项目已在多次联合举办的研讨会上进行了展示，并为成立一个新的组织——中医药与癌症国际联盟提供了背景，以促进该领域的国际合作。
